140 related articles for article (PubMed ID: 29256412)
1. Nephrotic syndrome under treatment with dasatinib: be aware of a possible adverse drug reaction.
Muller-Hansma AHG; van der Lugt J; Zwaan CM
Neth J Med; 2017 Dec; 75(10):428-431. PubMed ID: 29256412
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case report.
Ochiai S; Sato Y; Minakawa A; Fukuda A; Fujimoto S
BMC Nephrol; 2019 Mar; 20(1):87. PubMed ID: 30845905
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib-induced nephrotic syndrome.
Hirano T; Hashimoto M; Korogi Y; Tsuji T; Miyanaka K; Yamasaki H; Tsuda H
Leuk Lymphoma; 2016; 57(3):726-7. PubMed ID: 26436329
[No Abstract] [Full Text] [Related]
4. A case of dasatinib-induced focal segmental glomerulosclerosis in a patient with Philadelphia chromosome positive chronic myeloid leukemia.
Ersoy Yesil E; Sit D; Kayabasi H; Zerenler Gursoy F; Demirbas MB; Ocak Serin S
Nephrol Ther; 2021 Feb; 17(1):53-56. PubMed ID: 33431310
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
6. Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature.
Ruebner RL; Copelovitch L; Evageliou NF; Denburg MR; Belasco JB; Kaplan BS
Pediatr Nephrol; 2014 May; 29(5):863-9. PubMed ID: 24310825
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib-induced nephrotic syndrome: a case of phenoconversion.
Mandac Rogulj I; Matišić V; Arsov B; Boban L; Juginović A; Molnar V; Primorac D
Croat Med J; 2019 Jun; 60(3):250-254. PubMed ID: 31187953
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib-induced nephrotic-range proteinuria.
Wallace E; Lyndon W; Chumley P; Jaimes EA; Fatima H
Am J Kidney Dis; 2013 Jun; 61(6):1026-31. PubMed ID: 23540262
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus infection- and dasatinib-induced proteinuria in Ph+ALL.
Kawaguchi H; Tamura Y; Suzuki S; Asano-Murakoshi T; Nonoyama S
Pediatr Int; 2017 Jun; 59(6):740-741. PubMed ID: 28444835
[No Abstract] [Full Text] [Related]
11. Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.
Brattås MK; Reikvam H; Tvedt THA; Bruserud Ø
Expert Opin Investig Drugs; 2019 May; 28(5):411-420. PubMed ID: 30916583
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib-associated follicular lymphoma in a patient with B-cell acute lymphoblastic leukaemia.
Zhou KI; Lin C; Neff JL; Galal A
BMJ Case Rep; 2023 May; 16(5):. PubMed ID: 37197831
[TBL] [Abstract][Full Text] [Related]
13. Growth disturbances in children and adolescents receiving long-term tyrosine kinase inhibitor therapy for Chronic Myeloid Leukaemia or Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia.
Sabnis HS; Keenum C; Lewis RW; Patterson B; Bergsagel J; Effinger KE; Silverman E; Mertens AC; Castellino SM
Br J Haematol; 2019 May; 185(4):795-799. PubMed ID: 30407613
[No Abstract] [Full Text] [Related]
14. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib-induced chylothorax: report of a case and review of the literature.
Chen B; Wu Z; Wang Q; Li W; Cheng D
Invest New Drugs; 2020 Oct; 38(5):1627-1632. PubMed ID: 32248338
[TBL] [Abstract][Full Text] [Related]
16. Pneumocystis jiroveci pneumonia in patients receiving dasatinib treatment.
Chang H; Hung YS; Chou WC
Int J Infect Dis; 2014 Aug; 25():165-7. PubMed ID: 24932855
[TBL] [Abstract][Full Text] [Related]
17. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.
Mustjoki S; Ekblom M; Arstila TP; Dybedal I; Epling-Burnette PK; Guilhot F; Hjorth-Hansen H; Höglund M; Kovanen P; Laurinolli T; Liesveld J; Paquette R; Pinilla-Ibarz J; Rauhala A; Shah N; Simonsson B; Sinisalo M; Steegmann JL; Stenke L; Porkka K
Leukemia; 2009 Aug; 23(8):1398-405. PubMed ID: 19295545
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Keam SJ
BioDrugs; 2008; 22(1):59-69. PubMed ID: 18215092
[TBL] [Abstract][Full Text] [Related]
19. Spontaneous subdural hematoma in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with normal platelet count after dasatinib treatment.
Mustafa Ali MK; Sabha MM; Al-Rabi KH
Platelets; 2015; 26(5):491-4. PubMed ID: 25025538
[TBL] [Abstract][Full Text] [Related]
20. Clinical features, diagnosis, and management of dasatinib-induced nephrotic syndrome.
He Y; Fang W; Li Z; Wang C
Invest New Drugs; 2022 Oct; 40(5):1153-1159. PubMed ID: 35867286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
